Objective: To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).
Methods: The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep. 2014 to Sep. 2018 in the department of hematology, aerospace center hospital were retrospectively analyzed. Complications and disease-free survival after HSCT were observed.
Results: All the patients could well tolerate the conditioning regimen and acquired hematopoietic recon-struction. Following up till December 2018, with a median time of 11.5 months (1-51); acute GVHD developed in 2 cases and chronic GVHD developed in 5 cases, Among 6 cases one case died of viral pheumonia and the other 5 patients remained disease-free survival. The longest disease-free survival time has reached 51 months.
Conclusion: allo-HSCT is a safe and effective method for relapsed or refractory peripheral T-cell lymphoma, which can be chosen as salvage treatment method for patients with primary resistance. Optimization of the conditioning regimen may result in better efficacy of allo-HSCT.
题目: FLT3-ITD-mt和FLT3-ITD-wt初治原发AML患者外周血象和DNMT3A基因突变的临床特征对比.
目的: 比较初治原发急性髓系白血病（AML）FMS 样酪氨酸激酶3（FLT3）-内部串联重复野生型（ITD-wt）与突变型（FLT3-ITD-mt）患者临床特征的差异.
方法: 收集并回顾性研究本院2016年1月至2018年12月收治的108例初治原发AML患者的临床资料，根据是否伴有FLT3-ITD基因突变分为2组：A组（FLT3-ITD-wt）84例，B组（FLT3-ITD-mt）24例。对2组患者均行细胞形态学、分子生物学及免疫学分型检查，比较2组患者外周血红细胞数（RBC）、血红蛋白（Hb）水平、血小板数（Plt）、白细胞数（WBC）等血常规检查，骨髓原始细胞比例，FAB分型结果，融合基因分析及基因突变的发生情况等差异.
结果: B组外周血Hb和RBC水平相比A组明显下降（P<0.05），WBC计数明显升高（P<0.01）；而2组患者外周血Plt计数和骨髓原始细胞比例则无明显差异（P>0.05）。2组患者FAB分型结果无明显差异（P>0.05）。MLL-ELL、CBFβ-MYH11、PML-RARA及AML-ETO是初治原发AML患者的常见融合基因，而2组患者常见融合基因占比无明显差异（P>0.05）。本组108例患者共检出27种基因突变（包括FLT3-ITD在内）； B组DNMT3A基因突变检出率相比A组明显升高（P<0.05）；而2组其它基因突变检出率无明显差异（P>0.05）.
结论: FLT3-ITD-wt与FLT3-ITD-mt初治原发AML患者临床特征存在一定差异；与FLT3-ITD-wt比较，FLT3-ITD-mt的初治原发AML患者外周血Hb与RBC较低，而外周血WBC较高，且DNMT3A基因突变较多见.